Clinical Non-invasive Model to Predict Liver Inflammation in Chronic Hepatitis B With Alanine Aminotransferase ≤ 2 Upper Limit of Normal

Abstract

Background and Aim: Liver biopsy remains the gold standard for evaluating liver histology. However, it has certain limitations, and many patients refuse it. Non-invasive methods of liver evaluation are thus attracting considerable interest. In this study, we sought predictors of liver inflammation in chronic hepatitis B (CHB) patients with alanine aminotransferase (ALT) levels ≤ 2-fold the upper limit of normal (ULN); these may guide decisions on whether to commence antiviral therapy.

Methods: We retrospectively analyzed 720 patients with CHB who underwent liver biopsy and whose ALT levels were ≤2 ULN. The patients were randomly divided into a training and validation set. We used univariate and multivariate regression analyses of data from the training set to construct a model that predicted significant (grade ≥2) liver inflammation, and validated the model employing the validation set.

Results: Aspartate aminotransferase (AST) level, prothrombin time (PT), glutamyl transpeptidase (GGT) level, and anti-hepatitis B virus core antibody (anti-HBC) level were independent predictors of significant liver inflammation in CHB patients with ALT levels ≤ 2 ULN. A model featuring these four parameters afforded areas under the ROC curve of 0.767 and 0.714 for the training and validation sets. The model was more predictive than were the individual factors.

Conclusion: AST, GGT, anti-HBC, and PT reflect significant liver inflammation among CHB patients with ALT levels ≤ 2 ULN. Their combination indicates whether antiviral therapy is required.

Introduction

Hepatitis B virus (HBV) infection remains a serious public health problem worldwide. Persistent liver inflammation increases the risk of progression to cirrhosis and hepatocellular carcinoma (HCC) (1). Annually, over 1 billion CHB patients die from chronic liver disease, including cirrhosis and HCC (2). Early appropriate antiviral therapy can inhibit viral replication and prevent disease progression (3).

Treatment decisions for CHB patients are primarily based on the serum levels of alanine aminotransferase (ALT) and hepatitis B virus DNA (HBV-DNA), and the hepatic histological severity grade (grade ≥2 or S ≥2) (4). The AASLD guidelines recommend that patients with ALT levels ≤ 2 ULN, with moderate or severe inflammation, with significant fibrosis, or with elevated HBV-DNA levels should receive antiviral treatment (3). The EASL guidelines recommend that ALT ≥ ULN, moderate or severe inflammation, or significant fibrosis combined with an elevated HBV-DNA level should trigger treatment (1). Liver biopsy remains the gold standard for evaluating liver histology (5). However, the limitations include sampling error, limited dynamic evaluation of the histology, poor patient compliance, and poor intra- and inter-observer consistencies. Most patients are reluctant to undergo liver biopsy (6).

Many researcher seek to replace liver histology with non-invasive diagnostic models, including the aspartate aminotransferase (AST) and platelet (PLT) ratio index (APRI) (7); the FIB-4 test (based on age and ALT, AST, and PLT levels) (8); and the AST:ALT ratio (AAR) (9). These models are commonly used to assess liver fibrosis and cirrhosis. However, few such models have been used to evaluate liver necro-inflammation. There is an urgent need for a non-invasive predictive model based on serum markers that can accurately identify significant (grade ≥2) liver inflammation associated with CHB infection; such a model would facilitate early antiviral treatment decisions.

Materials and Methods

Patients

A total of 720 CHB patients with ALT levels ≤ 2 ULN who had undergone liver biopsies were retrospectively enrolled in the Department of Infectious Disease, Zhejiang Provincial People's Hospital, from October 2014 to December 2020. CHB infection was defined as hepatitis B surface antigen (HBsAg)-positivity for at least 6 months (10). The inclusion criteria were confirmed CHB infection and an ALT level ≤ 2 ULN (ULN = 40 U/L). The exclusion criteria were hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, co-infection with human immunodeficiency virus (HIV), another cause of chronic liver disease, alcoholic liver disease, autoimmune liver disease, non-alcoholic fatty liver disease (NAFLD), decompensated cirrhosis, HCC, an inadequate liver biopsy sample, and/or incomplete clinical laboratory data. The study was approved by the Ethics Committee of Zhejiang Provincial People's Hospital and all patients provided written informed consent.

Liver Biopsy

All patients underwent ultrasound-guided percutaneous liver biopsy using an 18 G needle. Biopsy specimens were fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin (H&E). Each specimen was required to be at least 1.5 cm in length and to contain at least six portal tracts. Histological grading of necro-inflammation (grade 0–4) followed the Scheuer classification system (11). All liver specimens were independently examined by two pathologists blinded to patient characteristics. Depending on the histological changes, patients were divided into a mildly affected group (grades 0–1) and a significantly affected group (grades 2–4).

Laboratory Tests

Demographic and laboratory data were collected prior to liver biopsy. We recorded age, sex, white blood cell (WBC) count, platelet (PLT) count, prothrombin time (PT), the international standardization ratio (INT), and levels of albumin (ALB), globulin (GLB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and serum total bilirubin (TBIL). Hepatitis B surface antigen (HBsAg), hepatitis B surface E antigen (HBeAg), and core antibody (anti-HBC) were detected using the CLIA system. The serum load of HBV-DNA was assessed via real-time polymerase chain reaction (ABI 7300 platform, Applied Biosystems, Foster City, CA, USA).

Statistical Analyses

All statistical analyses were performed using SPSS software ver. 21.0 (SPSS Inc./IBM, Chicago, IL, USA) and GraphPad Prism ver. 8.0.1 software. Continuous quantitative variables were compared using the Student t-test or the non-parametric Mann-Whitney test, and are expressed as means ± standard deviations (SDs) or as quartiles. Categorical variables were compared using the chi-square test, and are expressed as numbers or percentages. We used univariate analyses to identify factors significantly associated with necro-inflammatory grade. Then we subjected these variables to multivariate logistic regression to construct a predictive model. The area under the receiver operating characteristic curve (AUROC) was used to evaluate predictive accuracy. A two-tailed P-value < 0.05 was considered statistically significant.

Results

Demographic Data and Baseline Characteristics

We collected data on 983 CHB patients who underwent liver biopsy in Zhejiang Provincial People's Hospital from October 2014 to December 2020; we excluded 126 with ALT levels > 2 ULN. Of the remaining 826 patients, 10 had other liver diseases, 104 were excluded because of incomplete laboratory data, and 23 were excluded because their liver biopsy specimens were inadequate. Hence, 720 patients were enrolled and randomly divided into a training set (n = 430) and a validation set (n = 290) (Figure 1).

Figure 1

Table 1 lists all demographic and laboratory data. There were no significant differences between the training and validation sets (all P < 0.01). A total of 215 (50.0%) patients in the training set exhibited significant (grade ≥2) liver inflammation as did 138 (47.6%) patients in the validation set.

Univariate and Multivariate Logistic Regression

Univariate analyses revealed significant differences between mildly and significantly affected patients in terms of PT, WBC count, male sex, PLT count, and levels of ALB, GLB, GGT, HBeAg, AST, ALT, HBV-DNA, and anti-HBC (all P < 0.05) (Table 2). Multivariate logistic regression analyses revealed that AST, GGT, anti-HBC, and PT were independently associated with significant liver inflammation (see Table 3 for data).

Non-invasive Model Predicting Liver Histological Changes

For the training set, the performances of various parameters in terms of predicting significant liver inflammation (grades 2–4) are shown in Table 2. Univariate analyses indicated that PT, WBC, PLT, ALB, GLB, GGT, HBeAg, AST, ALT, HBV-DNA, and anti-HBC differed significantly between mildly affected (grade 0–1) and significantly affected (grade 2–4) patients (all P < 0.05) (Table 2). Multivariate logistic regression analyses indicated that PT, AST, GGT, and anti-HBC were independent predictors of disease severity (Table 3). The final model was:

Correlations Between PT, AST, GGT, and Anti-HBC Levels, and Liver Inflammation Grade

In the training set, PT, AST, GGT, and anti-HBC differed significantly between the seriously affected group (grade 2–4) and the mildly affected group (grade 0–1) (Figure 2). All of these were significantly lower in the latter patients than in the former patients. Therefore, a model based on these four parameters optimally predicted necro-inflammation levels in the liver.

Figure 2

Performance of the Four-Factor Combination

We drew ROC curves. Performance of the noninvasive model for predicting significant liver inflammation in the training set, validation set and total set are shown in Table 4 and Figure 3. The ROC curve of the predictive model for the training set is shown in Figure 3A; the AUROC was 0.767 (standard error [SE] 0.023; 95% CI 0.722–0.811; P < 0.001), higher than those for the individual variables. The model sensitivity and specificity for the training set were 66.0 and 76.7%, respectively. The ROC curve for the validation set is shown in Figure 3B; the AUROC was 0.714 (SE 0.030; 95% CI 0.655–0.773; P < 0.001), higher than those for the individual variables. The sensitivity and specificity were 67.4 and 67.8%, respectively.

Figure 3

Comparison of the Model With Other Non-invasive Models

We further evaluated the performance of other non-invasive models in terms of predicting significant liver inflammation in the training set. The AUROCs and 95% CIs of the various non-invasive models are listed in Table 5. In general, the diagnostic performances of other non-invasive models were lower than that of our model.

Discussion

Accurate assessment of the severity of liver inflammation plays an important role in control of disease progression, dictates subsequent treatment, and predicts prognosis. In recent years, many non-invasive models have been developed for evaluating liver fibrosis and cirrhosis (12, 13). However, few such models have been used to assess the severity of liver inflammation. Therefore, we constructed a non-invasive model to predict the liver inflammation grade of patients with ALT levels ≤ 2 ULN. The model features four independent predictors: AST, GGT, anti-HBC, and PT. The combination of the four parameters was more diagnostic than any individual parameter.

In patients with CHB, persistent liver inflammation is a major risk factor for the development of cirrhosis, HCC, and end-stage liver disease (5, 14). Early and accurate assessment of liver inflammation severity is important. Percutaneous liver biopsy remains the gold standard. However, biopsy is invasive and associated with certain complications (15). Therefore, we built a non-invasive model based on serum markers to predict liver necro-inflammation in CHB patients with ALT levels ≤ 2 ULN.

Currently, the serum ALT level is widely used to assess the severity of liver necro-inflammation (16). However, it is affected by multiple factors (17, 18). Most studies have reported severe liver damage in CHB patients with normal ALT levels (14, 19). In the present study, 215 (50.0%) patients in the training set and 138 (47.6%) in the validation set exhibited significant liver inflammation. An earlier study found that that 64 (37.0%) of 173 patients with ALT levels <64 IU/L evidenced moderate or severe inflammation (20). We consider that the ALT level alone does not adequately reflect the severity of liver inflammation or the appropriate timing of antiviral therapy in CHB patients with ALT levels ≤ 2 ULN. In addition, significant liver inflammation is a major risk factor for CHB progression to cirrhosis and HCC (5, 14).

Some studies have found that the AST level is better for diagnosing liver necro-inflammation than the ALT level (21). A Korean study found that the AST level predicted moderate or severe inflammation with high accuracy (AUROC = 0.78) in CHB patients with ALT levels ≤ 60 IU/L (21). We found that the AST level significantly increased as the liver inflammation grade increased; the level in CHB patients (ALT level ≤ 2 ULN) with significant inflammation was higher than that in patients with mild inflammation. The AST level well-predicted significant liver inflammation; the AUROC was 0.741. Therefore, AST levels should be closely monitored in CHB patients.

Liver injury has many causes. When liver function is impaired, inflammation and cell necrosis activate the coagulation system, and consumption of coagulation-related substances in the liver triggers coagulation dysfunction. The PT reflects the severity of inflammation. The PT was an independent predictor of liver necro-inflammation. As the liver inflammation grade increased, the PT increased; that of the moderate or severe inflammation group was higher than that of the mild inflammation group. The PT reflects hepatocyte synthesis and is associated with a poor prognosis of significant liver inflammation (22). Hepatocyte function and prognosis worsen as the PT increases (22). A PT >5 s that of the control value is prognostic of serious liver disease (23).

The GGT level sensitively reflects the extent of necro-inflammation. It better predicts necro-inflammation than the ALT level, and is an important predictor in patients with HBV infection (2, 24, 25). We found that it independently predicted significant liver inflammation (OR = 1.014, P = 0.042). Previous studies have also found that GGT level is a risk factor for significant liver inflammation in patients with HBV infection (24, 26, 27).

The anti-HBC level, a serological marker of HBV infection, can be used to accurately assess moderate or severe inflammation in CHB patients with normal ALT levels (28). One study found that anti-HBC level is independently associated with moderate or severe inflammation in CHB patients with normal ALT levels, with high diagnostic performance (29). Another study showed that anti-HBC level can be used to accurately identify moderate or severe inflammation (AUROCs = 0.768 and 0.767) in CHB patients with ALT levels <64 IU/L (20). We found that the anti-HBC level was a highly accurate independent predictor of liver necro-inflammation (OR 0.824; 95% CI 0.743–0.914; P < 0.001). In patients with normal ALT levels, the anti-HBC level increased with increasing liver inflammation, consistent with previous studies (20, 29). However, the mechanism by which anti-HBC antibodies affect liver inflammation during HBV infection remains unclear. Some studies have suggested that the anti-HBC level may affect the responses of B and T lymphocytes (30, 31). The mechanism by which anti-HBC antibody induces hepatocyte injury requires further study.

Our model predicted significant necro-inflammatory activity in the training set; the AUROC was 0.767 (95% CI 0.722–0.811). At a cutoff of 0.56 (the maximum Youden index point) the sensitivity and specificity were 66.0 and 76.7%, respectively. We tested low (0.27) and high (0.64) Youden index cutoffs. The model predicted significant liver inflammation in 183 patients (42.6%) of the training set. Thus, the model was highly accurate, rendering liver biopsy unnecessary for many CHB patients. We also evaluated the performances of other non-invasive models in terms of predicting significant liver inflammation. Most exhibited high diagnostic performances.

An advantage of our model is that it uses routine laboratory data only. A limitation of this study is that it was retrospective in nature. In addition, all 720 patients were enrolled from the same institution. A large multicenter study is required. In addition, our results differ from those of other non-invasive methods; combinations with other methods require study. Finally, the mechanisms of action of the four independent variables (in terms of inducing liver inflammation) remain unclear.

In conclusion, we constructed a non-invasive model based on serological markers. The PT and levels of AST, GGT, and anti-HBC independently predicted significant liver inflammation in CHB patients with ALT levels ≤ 2 ULN. The diagnostic performances were high for both the training and validation sets; the model may reduce the need for liver biopsy.

Summary

In patients with chronic hepatitis B, persistent liver inflammation is a major risk factor for the development of cirrhosis, hepatocellular carcinoma (HCC) and end-stage liver disease. Therefore, early and accurate assessment the severity of liver inflammation is pretty important for the prognosis of patients. However, clinical application of liver biopsy is limited due to its invasiveness and associated complications. Moreover, most non-invasive models have been developed for the evaluation of liver fibrosis and cirrhosis. Few non-invasive models were used to assess liver necro-inflammation. Therefore, we constructed a non-invasive model based on serum markers for predicting liver necro-inflammation in CHB patients with alanine aminotransferase (ALT) ≤2 upper limit of normal. Aspartate aminotransferase (AST), prothrombin time (PT), glutamyl transpeptidase (GGT) and anti-hepatitis B virus core antibody (Anti-HBC) were related to significant (G ≥2) liver inflammation among CHB patients with ALT ≤2ULN. Combined with AST, PT, GGT and Anti-HBC to construct a model, with area under the ROC curve (AUROC) of 0.767 and 0.714 in training and validation set. The combined indicators have a better diagnostic performance, which may help to reduce the need for clinical liver biopsy, to determine whether to need antiviral therapy.

References

• 1.

  European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. (2017) 67:370–98. 10.1016/j.jhep.2017.03.021

  • CrossRef
  • Google Scholar
  • View reference in article

• 2.

  ZengMDLuLGMaoYMQiuDKLiJQWanMBet al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. (2005) 42:1437–45. 10.1002/hep.20960

  • CrossRef
  • Google Scholar
  • View reference in article

• 3.

  TerraultNALokASFMcMahonBJChangKMHwangJPJonasMMet al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. (2018) 67:1560–99. 10.1002/hep.29800

  • CrossRef
  • Google Scholar
  • View reference in article

• 4.

  European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. (2012) 57:167–85. 10.1016/j.jhep.2012.02.010

  • CrossRef
  • Google Scholar
  • View reference in article

• 5.

  SarinSKKumarMLauGKAbbasZChanHLYChenCJet al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. (2015) 10:1–98. 10.1007/s12072-015-9675-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 6.

  CadranelJFRufatPDegosF. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. (2000) 32:477–81. 10.1053/jhep.2000.16602

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 7.

  WaiCTGreensonJKFontanaRJKalbfleischJDMarreroJAConjeevaramHSet al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. (2003) 38:518–26. 10.1053/jhep.2003.50346

  • CrossRef
  • Google Scholar
  • View reference in article

• 8.

  SterlingRKLissenEClumeckNSolaRCorreaMCMontanerJet al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. (2006) 43:1317–25. 10.1002/hep.21178

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 9.

  DongMWuJYuXLiJYangSQiXet al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int. (2018) 38:1562–70. 10.1111/liv.13688

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  LokASMcMahonBJ. Chronic hepatitis B. Hepatology. (2007) 45:507–39. 10.1002/hep.21513

  • CrossRef
  • Google Scholar
  • View reference in article

• 11.

  ScheuerPJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. (1991) 13:372–4. 10.1016/0168-8278(91)90084-O

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12.

  AfdhalNHNunesD. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. (2004) 99:1160–74. 10.1111/j.1572-0241.2004.30110.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13.

  MartinezSMCrespoGNavasaMFornsX. Noninvasive assessment of liver fibrosis. Hepatology. (2011) 53:325–35. 10.1002/hep.24013

  • CrossRef
  • Google Scholar
  • View reference in article

• 14.

  TrépoCChanHLYLokA. Hepatitis B virus infection. The Lancet. (2014) 384:2053–63. 10.1016/S0140-6736(14)60220-8

  • CrossRef
  • Google Scholar
  • View reference in article

• 15.

  RegevABerhoMJeffersLJMilikowskiCMolinaEGPyrsopoulosNTet al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. (2002) 97:2614–8. 10.1111/j.1572-0241.2002.06038.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16.

  KimWRFlammSLBisceglieDi. AM, Bodenheimer HC, Public Policy Committee of the American Association for the Study of Liver D. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. (2008) 47:1363–70. 10.1002/hep.22109

  • CrossRef
  • Google Scholar
  • View reference in article

• 17.

  SharaihaRZKumtaNASaumoyMDesaiAPSarkisianAMBenevenutoAet al. Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. Clin Gastroenterol Hepatol. (2017) 15:504–10. 10.1016/j.cgh.2016.12.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18.

  OuHCaiSLiuYXiaMPengJ. A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Ther Adv Gastroenterol. (2016) 10:207–17. 10.1177/1756283X16681707

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 19.

  AlamSAhmadNMustafaGShresthaAAlamAKKhanM. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B. Liver Int. (2011) 31:824–30. 10.1111/j.1478-3231.2011.02491.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 20.

  LiJZhangTYSongLWQiXYuXPFHLiet al. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. Hepatol Res. (2018) 48:E133–45. 10.1111/hepr.12937

  • CrossRef
  • Google Scholar
  • View reference in article

• 21.

  CheongJYKimDJHwangSGYangJMKimYBParkYNet al. Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. Liver Int. (2011) 31:1352–8. 10.1111/j.1478-3231.2011.02570.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 22.

  LiXMMaLYangYBShiZJZhouSS. Analyses of prognostic indices of chronic liver failure caused by hepatitis virus. World J Gastroenterol. (2005) 11:2841–3. 10.3748/wjg.v11.i18.2841

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 23.

  WoretaTAAlqahtaniSA. Evaluation of abnormal liver tests. Med Clin North Am. (2014) 98:1–16. 10.1016/j.mcna.2013.09.005

  • CrossRef
  • Google Scholar
  • View reference in article

• 24.

  MyersRPTainturierM-HRatziuVPitonAThibaultVImbert-BismutFet al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatology. (2003) 39:222–30. 10.1016/S0168-8278(03)00171-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 25.

  CasteraL. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. (2012) 142:1293–302. 10.1053/j.gastro.2012.02.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 26.

  YuYFanYYangZLuYXuQChenX. Elevated serum gamma-glutamyltransferase predicts advanced histological liver damage in chronic hepatitis B. Discov Med. (2016) 21:7–14.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 27.

  WangHXueLYanRZhouYWangMSChengMJet al. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS ONE. (2013) 8:e80585. 10.1371/journal.pone.0080585

  • CrossRef
  • Google Scholar
  • View reference in article

• 28.

  HoofnagleJHSeeffLBBalesZBZimmermanHJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. (1978) 298:1379–83. 10.1056/NEJM197806222982502

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 29.

  ZhouJSongLZhaoHYanLMaAXieSet al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. Sci Rep. (2017) 7:2747. 10.1038/s41598-017-03102-3

  • CrossRef
  • Google Scholar
  • View reference in article

• 30.

  ZgairAKGhafilJAAl-SayidiRH. Direct role of antibody-secreting B cells in the severity of chronic hepatitis B. J Med Virol. (2015) 87:407–16. 10.1002/jmv.24067

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  OlivieroBCerinoAVarchettaSPaudiceEPaiSLudovisiSet al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol. (2011) 55:53–60. 10.1016/j.jhep.2010.10.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar